UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

79 Biomarker of response to immunotherapy

Radiotherapy and oncology, 2024-03, Vol.192, p.S7-S9

Nenclares, Pablo

2024

Volltextzugriff (PDF)

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Nature communications, 2024-08, Vol.15 (1), p.6923-16, Article 6923

2024

Volltextzugriff (PDF)

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade

Journal for immunotherapy of cancer, 2022-03, Vol.10 (3), p.e004306

2022

Volltextzugriff (PDF)

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002718

2021

Volltextzugriff (PDF)

T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies

Frontiers in oncology, 2024-01, Vol.13, p.1296948-1296948

2024

Volltextzugriff (PDF)

Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma

iScience, 2024-09, Vol.27 (9), p.110635, Article 110635

2024

Volltextzugriff (PDF)

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling

Journal for immunotherapy of cancer, 2024-07, Vol.12 (7), p.e009443

2024

Volltextzugriff (PDF)

507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A539-A539

2021

Volltextzugriff (PDF)

The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy?

BJC Reports, 2024-09, Vol.2 (1), Article 68

2024

Volltextzugriff (PDF)

Taste dysfunction following radiotherapy to the head and neck: A systematic review

Radiotherapy and oncology, 2021-04, Vol.157, p.130-140

2021

Volltextzugriff (PDF)

Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy

European journal of cancer (1990), 2020-05, Vol.131, p.9-15

2020

Volltextzugriff (PDF)

Management of Head and Neck Mucosal Melanoma

Oral and maxillofacial surgery clinics of North America, 2022-05, Vol.34 (2), p.299-314

2022

Volltextzugriff (PDF)

Head and neck mucosal melanoma: The United Kingdom national guidelines

European journal of cancer (1990), 2020-10, Vol.138, p.11-18

2020

Volltextzugriff (PDF)

Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9527-9527

2023

Volltextzugriff (PDF)

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

European journal of cancer (1990), 2020-09, Vol.136, p.99-106

2020

Volltextzugriff (PDF)

Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9511-9511

2024

Volltextzugriff (PDF)

FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (10), p.1560-1569

2024

Volltextzugriff (PDF)

Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway

Oral oncology, 2018-04, Vol.79, p.55-63

2018

Volltextzugriff (PDF)

A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2704-TPS2704

2022

Volltextzugriff (PDF)

What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?

Head & neck, 2021-11, Vol.43 (11), p.3498-3503

2021

Volltextzugriff (PDF)

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

The Journal of clinical investigation, 2024-01, Vol.134 (2), p.1-14

2024

Volltextzugriff (PDF)

Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.LB180-LB180

2021

Volltextzugriff (PDF)

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition

Journal of laryngology and otology, 2024-04, Vol.138 (S1), p.S1-S224

2024

Volltextzugriff (PDF)

Abstract 2467: Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2467-2467

2024

Volltextzugriff (PDF)

Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations

American Society of Clinical Oncology educational book, 2022-04, Vol.42 (42), p.1-526

2022

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

79 Biomarker of response to immunotherapy

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade

On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy

T-cell receptor determinants of response to chemoradiation in locally-advanced HPV16-driven malignancies

Cancer cell – Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T-cell receptor signalling

507 A phase 1 clinical trial of RP2, an enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody, as a single agent and combined with nivolumab in patients with advanced solid tumors

The impact of elective cervical lymph node treatment on the tumour immune response in head and neck squamous cell carcinoma: time for a change in treatment strategy?

Taste dysfunction following radiotherapy to the head and neck: A systematic review

Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy

Management of Head and Neck Mucosal Melanoma

Head and neck mucosal melanoma: The United Kingdom national guidelines

Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma

Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer

Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma

FUME-TCRseq Enables Sensitive and Accurate Sequencing of the T-cell Receptor from Limited Input of Degraded RNA

Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway

A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors

What is the role of the surgeon in the management of head and neck mucosal melanoma in the immunotherapy era?

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

Abstract LB180: Clinical biomarker studies with two fusion-enhanced versions of oncolytic HSV (RP1 and RP2) alone and in combination with nivolumab in cancer patients indicate potent immune activation

Head and Neck Cancer: United Kingdom National Multidisciplinary Guidelines, Sixth Edition

Abstract 2467: Enhanced CD8+T-cell infiltration, PD-L1 expression, and T-cell repertoire expansion in patients with metastatic uveal melanoma responding to treatment with RP2 alone or in combination with nivolumab

Introducing Checkpoint Inhibitors Into the Curative Setting of Head and Neck Cancers: Lessons Learned, Future Considerations

Suchergebnisse filtern